Identifying Candidates for Active Surveillance: An Evaluation of the Repeat Biopsy Strategy for Men with Favorable Risk Prostate Cancer
Abstract
Purpose:
Active surveillance is increasingly recommended to reduce overtreatment in men with favorable risk prostate cancer. A repeat confirmatory biopsy has become the standard recommendation for these men to increase the precision of this risk attribution. We investigate the usefulness of this approach by comparing the current practice standard, repeat transrectal ultrasound biopsy, with template prostate mapping.
Materials and Methods:
A total of 124 men who were attributed a favorable risk prostate cancer status based on transrectal ultrasound guided biopsy and who were considering a policy of active surveillance underwent combined transrectal ultrasound biopsy and template prostate mapping as a confirmatory strategy. Maximum Gleason grade and disease burden were compared between the 2 confirmatory tests.
Results:
Depending on the definition used between 8% and 22% of men had prostate cancer reclassified as clinically important by repeat transrectal ultrasound biopsy whereas template guided prostate mapping reclassified the disease in 41% to 85% of the men. Repeat transrectal ultrasound biopsy failed to detect up to 80% of clinically important cancers detected by the reference standard. The sensitivity of repeat transrectal ultrasound biopsy to identify clinically important disease varied from 9% to 24% with the negative predictive value ranging from 23% to 60%.
Conclusions:
When applied to a population of men initially deemed to have favorable risk prostate cancer, transrectal ultrasound biopsy will miss a large proportion of clinically important cancers compared to template guided prostate mapping. The usefulness of repeat transrectal ultrasound biopsy in ruling out clinically important prostate cancer needs to be reconsidered.
References
- 1 : Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol2010; 28: 126. Google Scholar
- 2 : Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol2011; 29: 228. Google Scholar
- 3 : Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol2011; 29: 2185. Google Scholar
- 4 : Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. Urology2008; 72: 177. Google Scholar
- 5 : Does prostate biopsy Gleason score accurately express the biologic features of prostate cancer?. Urol Oncol2007; 25: 383. Google Scholar
- 6 : The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU Int2011; 108: 371. Google Scholar
- 7 : Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol2010; 183: 1779. Link, Google Scholar
- 8 : Transperineal template guided saturation biopsy of the prostate: rationale, indications and technique. Urology Times2003; 31: 41. Google Scholar
- 9 : Transperineal 3-dimensional pathological mapping for stratification of risk in patients seeking expectant management for low volume prostate cancer. J Urol2007; 177: 248. abstract 738. Link, Google Scholar
- 10 : Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate–a 4-year experience. Urology2007; 70: 27. Google Scholar
- 11 : Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA1994; 271: 368. Google Scholar
- 12 : Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer1993; 71: 3582. Google Scholar
- 13 : Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol1996; 156: 1059. Link, Google Scholar
- 14 : Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol2011; 186: 458. Link, Google Scholar
- 15 : Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer Prostatic Dis2010; 13: 71. Google Scholar
- 16 : Transperineal prostate biopsy: analysis of a uniform core sampling pattern that yields data on tumor volume limits in negative biopsies. Theor Biol Med Model2010; 7: 23. Google Scholar
- 17 : Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol2009; 27: 4321. Google Scholar
- 18 : Systematic transperineal ultrasound-guided template biopsy of the prostate: three-year experience. Urology2005; 65: 735. Google Scholar
- 19 : Extensive transperineal template biopsies of prostate: modified technique and results. Urology2006; 68: 1037. Google Scholar
- 20 : The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. J Urol2011; 186: 80. Link, Google Scholar
- 21 : Screening and prostate-cancer mortality in a randomized European study. N Engl J Med2009; 360: 1320. Google Scholar
- 22 : Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ2010; 341: c4543. Google Scholar
- 23 : Is it time to consider a role for MRI before prostate biopsy?. Nat Rev Clin Oncol2009; 6: 197. Google Scholar
- 24 : D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol2011; 185: 815. Link, Google Scholar
- 25 : Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int2011; 108: E171. Google Scholar
- 26 : Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol2010; 183: 520. Link, Google Scholar
